Pharmaceuticals company Hikal announced Q3FY25 results Revenue: Rs 448 crore compared to Rs 448 crore during Q3FY24. EBITDA: Rs 72 crore compared to Rs 65 crore during Q3FY24. EBITDA margin: 16.1% for Q3FY25. PAT: Rs 17 crore compared to Rs 16 crore during Q3FY24. Jai Hiremath, Executive Chairman, Hikal, said: “In the global pharmaceutical industry, we are witnessing positive momentum led by CDMO opportunities while the crop protection industry is showing signs of stabilization. In Q3FY25, our revenue amounted to Rs 448 crore, with an EBITDA of Rs 72 crore, a 11% EBITDA growth on YoY basis. For the 9MFY25, revenue stood at Rs 1307 crore, with an EBITDA of Rs 205 crore, a growth of 3% and 19% respectively. The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped us to improve our margin profile. Our focused business initiatives have resulted in increased operating cash flows of Rs 102 crore YoY on 9 months basis. Our Board of Directors has recommended an interim dividend of Rs 0.60 per share (30%). In Q3FY25, our pharmaceutical revenue stood at Rs 293 crore with EBIT margin of 11.4%, an increase of 449 bps, on a YoY basis. Our CDMO business continues to see an increasing flow of new enquiries as a result of the China+1 strategy by global pharmaceutical companies. We are confident to deliver profitable growth based on a healthy pipeline of projects in various phases of the life cycle. Our API segment continues to gain traction driven by improved geographical penetration and an increased customer base. In Q3FY25, our crop protection revenue stood at Rs 154 crore, with an EBIT margin of 9%. The sector has started to exhibit signs of stabilization, predominantly driven by domestic markets. We are seeing a marginal recovery in volumes, although global market prices for actives continue to remain low. In our animal health segment, the project under our long-term agreement with an innovator customer is progressing well and we will conclude the validation over the next two quarters. Our products are undergoing registration and ultimately launching these products in global markets. Under our strategic transformation initiative - Pinnacle, we continue to make substantial strides toward achieving sustainable growth across our businesses. We are witnessing early signs of success in development of new capabilities and differentiated technology platform as well as customers base expansion. We have successfully integrated sustainable practices into our ESG initiatives.” Result PDF